...
首页> 外文期刊>Journal of Infection >Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections.
【24h】

Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections.

机译:耐亚胺培南的铜绿假单胞菌血流感染的临床影响。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To describe the incidence and clinical characteristics of imipenem-resistant (IR) Pseudomonas aeruginosa bacteraemia. METHODS: We performed a retrospective study including all episodes of IR P. aeruginosa bacteraemia seen from January 2003 to December 2005 in a tertiary teaching hospital. RESULTS: There were 108 episodes of IR P. aeruginosa bacteraemia, which represented an incidence of 0.14 episodes per 1000 patient-days in 2003 and 0.11 episodes per 1000 patient-days in 2005. 83 of the episodes (77%) were nosocomially acquired. Most of patients had at least one underlying disease and had previously received antimicrobial treatment. The most frequent source was the urinary tract (31%), followed by unknown origin (22%). A total of 23 (21%) episodes were polymicrobial and 51 (47%) were caused by multidrug-resistant strains. The independent risk factors for mortality from IR P. aeruginosa bloodstream infection were a high-risk source of the bacteraemia (OR: 4.6; 95% CI 1.7-12.4; p=0.01), and presentation with severe sepsis (OR: 2.8; 95% CI 1-7.8; p=0.05). CONCLUSIONS: Our study shows that the rates of IR P. aeruginosa bacteraemia remained stable throughout the study period. The source of bacteraemia and the clinical presentation with severe sepsis were the main determinants of the prognosis.
机译:目的:描述亚胺培南耐药(IR)的铜绿假单胞菌菌血症的发生率和临床特征。方法:我们进行了一项回顾性研究,包括2003年1月至2005年12月在一家三级教学医院发现的所有IR铜绿假单胞菌菌血症发作。结果:IR铜绿假单胞菌菌血症有108次发作,2003年为每1000个患者日0.14次发作,2005年为每1000个患者日0.11次发作。其中83次(77%)是医院内获得的。大多数患者至少有一种基础疾病,以前曾接受过抗菌治疗。最常见的来源是尿路(31%),其次是未知来源(22%)。共有23次(21%)发作是多菌种,其中51次(47%)是由多重耐药菌株引起的。导致铜绿假单胞菌血液感染死亡的独立危险因素是菌血症的高风险来源(OR:4.6; 95%CI 1.7-12.4; p = 0.01),并伴有严重败血症(OR:2.8; 95) %CI 1-7.8; p = 0.05)。结论:我们的研究表明,在整个研究期间,IR铜绿假单胞菌菌血症的发生率保持稳定。菌血症的来源和严重脓毒症的临床表现是影响预后的主要因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号